Leuko’s PointCheck medical device can non-invasively measure white blood cells from a patient’s home. Credit: Leuko / Business Wire.

Leuko has been awarded a $4.5m grant from the National Institutes of Health (NIH) to advance the development of its non-invasive white blood cell monitoring device, PointCheck.

The Small Business Innovation Research (SBIR) Phase IIB award from the NIH National Cancer Institute (NCI) will help Leuko expedite the development of PointCheck and assist in gathering clinical evidence necessary for the technology’s commercialisation.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Leuko’s PointCheck is an at-home, non-invasive monitor designed to provide healthcare professionals with a more comprehensive view of patient health remotely.

The device uses light to examine the skin at the fingernail’s top and employs advanced algorithms to determine when white blood cell levels become critically low.

This approach to blood cell count monitoring could potentially eliminate the need for traditional blood samples.

See Also:

The device could facilitate early detection of at-risk patients and prompt preventive treatments to avert infections, potentially reducing hospital admissions and enhancing clinical outcomes.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Leuko co-founder and CEO Carlos Castro-Gonzalez said: “At Leuko, we are committed to delivering on our vision for non-invasive blood testing, which could transform how cancer patients and other immunocompromised populations are managed.

“Thanks to this NIH grant, we will advance to the next stage of clinical development and move closer to making this technology widely available to patients.”

Leuko, which emerged from collaborations between the Massachusetts Institute of Technology and the Madrid M+Vision Consortium, aims to transform patient care by enabling frequent, at-home monitoring.

In 2022, Leuko raised $5m in Series A funding to validate its PointCheck solution for people with cancer.

HTH VC, Nina Capital, IAG Capital Partners, Good Growth Capital and angel investors contributed to the funding.